Sheila Ranganath

Sheila Ranganath joined Flagship Pioneering in 2022 as Vice President of Program Leadership for Pioneering Medicines.
She is responsible for leading multidisciplinary teams and collaborations between Pioneering Medicines, Flagship platform companies, and external partners for early discovery through early clinical development stage programs.
Sheila brings over 15 years of industry experience from biotech and pharma to Pioneering Medicines.
Prior to joining Flagship, she was Vice President, Biology at LifeMine Therapeutics where she led the Discovery and Translational Biology group and oversaw the New Target Evaluation team.
Previously, she was Director, Immunobiology in the Discovery Oncology group at Merck where she supported Keytruda combination strategy; led several multidisciplinary teams to develop drug candidates in different modalities; oversaw and supported several early clinical development programs; and led academic collaborations.
Prior to Merck, Sheila she spent ten years in positions of increasing responsibility at Pfizer, Ironwood Pharmaceuticals, and Enumeral Biomedical.
Sheila has co-authored over 25 publications and contributed to articles published in Nature, Immunity, and the Journal of Immunology.
Sheila received a B.A.
in Molecular and Cellular Biology from the University of California, Berkeley, a Ph.D.
in Immunology from Washington University in St. Louis and completed postdoctoral training at Harvard Medical School.